- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03601598
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
A Phase Ib/II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With A CDK4/6 Inhibitor SHR6390 in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma
This is a Phase Ib/II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With SHR6390 (a CDK4/6 Inhibitor) in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and Hepatocellular Carcinoma.
The study was designed in two stages, the first stage was the tolerance observation stage, and the second stage was the curative effect expansion stage.
The first part of the study is the Dose-finding Phase designed to establish the safety of SHR-1210 Combination With SHR6390 at different dose Levels(150mg QD or 100mg QD ). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses .
This study aims to evaluate the safety and efficacy of SHR-1210 combination with SHR6390 in the treatment of advanced CRC,NSCLC and HCC.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yanqiao Zhang, PhD
- Phone Number: 138 4512 0210
- Email: yanqiaozhang@126.com
Study Contact Backup
- Name: Guangyu Wang, PhD
- Phone Number: 18249038966
- Email: 18249038966@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects voluntarily participate in this study and sign informed consent .
- Men or women aged 18-75 years
- Has confirmed by histology and cytology advanced and/or metastatic colorectal cancer patients, the advanced (Ⅲ B/Ⅳ period) in non-small cell lung cancer,Or patients with advanced hepatocellular carcinoma confirmed histologically or cytologically or clinically,At least one measurable lesion that meets the RECIST v1.1 criteria without local treatment.
- The patients can swallow pills normally.
- ECOG score was 0 or 1.
- Have a life expectancy of at least 12 weeks.
- The functions of vital organs meet the following requirements (excluding the use of any blood components and cytokines during screening) : Neutrophils≥1.5 x 109/L, Hb≥9g/dL; Plt≥90 x 109/L, ALB≥3g/dL, TSH≤ULN(Upper Limit Of Norma), TBIL ≤ 1.25 x ULN, ALT and AST ≤ 1.5 x ULN, AKP≤ 2.5 x ULN, CR≤ 1.5 x ULN
- Female Subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 3 months after the last dose of study treatment.
Exclusion Criteria:
- Subjects had any active autoimmune disease or history of autoimmune disease.
- Subjects are using immunosuppressive agents, or systemic, or absorptive,local hormone therapy to achieve immunosuppression. It is still in use within 2 weeks before enrollment.
- Subjects with severe allergic reactions to other monoclonal antibodies.
- The subjects had a central nervous system metastases of clinical symptoms.
- Central lung squamous cell carcinoma, or NSCLC with large vascular invasion confirmed by imaging.
- A heart condition or disease that is not well controlled.
- Subjects had active infections.
- Other clinical trials of drugs were used within 4 weeks prior to the first administration.
- The subjects have received other PD-1 antibody therapy or other immunotherapy for PD-1 / PD-L1 or CDK4/6 inhibitor treatment in the past.
- There are other factors lead to patients can not participate in this clinical study by the judgment of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SHR-1210 + SHR6390
SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
|
SHR-1210 was administered 200mg iv every 2 weeks
SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR(phase II)
Time Frame: from the first drug administration up to two years
|
Overall Response Rate
|
from the first drug administration up to two years
|
MTD /DLT (phase Ib)
Time Frame: Within four weeks after dosing
|
Maximum Tolerated Dose/Dose Limiting Toxicity
|
Within four weeks after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR(phase Ib)
Time Frame: from the first drug administration up to two years
|
Overall Response Rate
|
from the first drug administration up to two years
|
Incidence of Treatment-Emergent Adverse Events (phase Ib/II)
Time Frame: from the first drug administration to within 90 days for the last SHR-1210 dose
|
adverse events/serious adverse events
|
from the first drug administration to within 90 days for the last SHR-1210 dose
|
CBR (phase Ib/II)
Time Frame: from the first drug administration up to last patients treatment for 6 months.
|
Clinical Benefit Rate
|
from the first drug administration up to last patients treatment for 6 months.
|
DoR (phase Ib/II)
Time Frame: from the first drug administration up to two years
|
Duration of response
|
from the first drug administration up to two years
|
PFS(phase Ib/II)
Time Frame: from the first drug administration up to two years
|
Progression-Free-Survival
|
from the first drug administration up to two years
|
TTR(phase Ib/II)
Time Frame: from the first drug administration up to one year
|
Time to Response
|
from the first drug administration up to one year
|
12m-OS
Time Frame: 12 months after the first drug administration
|
12 months Overall survival
|
12 months after the first drug administration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: yanqiao zhang, phD, Harbin Medical University Cancer Hosptital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SHR-1210-SHR6390-IIT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on SHR-1210
-
Tianjin Medical University Cancer Institute and...Not yet recruitingEsophageal Squamous Cell Carcinoma | Progression to PD-1 AntibodyChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
The First Affiliated Hospital of Zhengzhou UniversityNot yet recruitingResectable Esophageal Squamous Cell Carcinoma
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.RecruitingSarcomatoid Carcinoma of LungChina
-
Guangdong Association of Clinical TrialsNot yet recruitingNon-small Cell Lung Cancer
-
Beijing Sanbo Brain HospitalRecruitingPrimary Central Nervous System LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedLung NeoplasmsChina
-
Guangdong Association of Clinical TrialsUnknown
-
Yanqiao ZhangNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Completed